The Next Agonist

The class is moving: the melanocortin sun drugs actually in trials now

By Tan Lines·Published September 24, 2026

The gray market froze Melanotan II in amber around 2008 — the same peptide, the same vials, the same warnings that never quite worked. It is easy to mistake that stillness for the state of the whole field. It isn’t. Behind the vial, the legitimate melanocortin drug class has kept moving, and in 2026 it moved more than it has in years. This file is a snapshot of where the real programs stand — the ones with trial registries, endpoints, and regulators attached — kept honest about what they are and, more importantly, what they are not.

Nothing below is a tan you can buy. Read it instead as the answer to the question this site’s Next Agonist thread keeps asking: is the science that escaped the lab finding its way back through the front door? The answer, right now, is yes — slowly, and never toward the use the gray market wanted.

The headline: an MC1R agonist you swallow

For the entire gray-market era the technology had one shape — a peptide you had to inject, because peptides don’t survive the gut. That constraint is breaking.

Dersimelagon (MT-7117), developed by Tanabe Pharma, is a non-peptide, orally available selective agonist of the melanocortin-1 receptor — the same receptor at the center of how the tanning signal works. A pill, not a needle. In 2026 its global, double-blind Phase 3 study — INSPIRE, 165 patients — met its primary endpoint with a safety profile the sponsor described as favourable, most adverse events mild to moderate. The FDA accepted the New Drug Application, granted it priority review, and a decision is expected around the end of February 2027.

Read that carefully, because it is both more and less than it sounds.

More, because oral bioavailability is exactly the delivery breakthrough the middle-ground file named as missing. A clinic-administered implant is a rare-disease format; a daily oral agonist is, in principle, a mass-market one. The chemistry that the gray market proved people wanted — and that afamelanotide proved could be approved — now exists in a form you take like any other tablet.

Less, because the indication is, once again, narrow: erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), the same rare light-pain disorders afamelanotide serves. The endpoint that got dersimelagon this far was time to first sun-triggered symptom in people whose skin burns in minutes — not sun damage prevented in the general public. The molecule cleared the bar. The label did not widen. It is the exact pattern this site has been describing, now repeating with an oral drug instead of an implant.

The incumbent, quietly broadening

The other live program belongs to the drug that already made it: afamelanotide (Scenesse), approved for EPP in the EU in 2014 and by the FDA in 2019. What’s changed is that its maker is no longer treating EPP as the ceiling. Afamelanotide is now in clinical study across a spread of indications that, taken together, sketch the outline of a general photomedicine:

• Non-segmental vitiligo — a Phase III program (CUV105, with a pivotal CUV107 study of around 300 patients planned to begin in the second half of 2026) testing whether driving eumelanin can repigment skin that has lost its colour. In April 2026 the sponsor secured final EMA scientific advice on the pivotal design. This is the mirror image of tanning: the same pigment machinery, pointed at restoring colour rather than adding it.
• Xeroderma pigmentosum (XP) — a study (CUV156) evaluating safety in XP-C patients and, tellingly, the drug’s ability to assist reparative processes after UV-provoked DNA damage. This is the frontier claim: not just pigment as a sunshade, but melanocortin signalling as an input to DNA repair. If it holds up, it reframes what “photoprotection” even means.
• Variegate porphyria and arterial ischaemic stroke round out the list — neither cosmetic, both far afield from a tan, both evidence that the receptor family reaches into biology the gray market never advertised.

The delivery format is still the specialty implant, and every one of these is a disease indication with its own trial and its own regulator. But the direction is unmistakable: the approved molecule is being pushed outward, indication by indication, toward the kinds of broad-population, repair-and-protection claims that a true consumer photoprotective would eventually need.

What this snapshot does and doesn’t show

Line the two programs up and the shape of the field in 2026 is clearer than it has been since the Arizona lab:

• Delivery is being solved. Oral MC1R agonism is no longer hypothetical — it is under FDA review.
• The indication ladder is real. EPP was the beachhead; vitiligo and DNA-repair studies are the next rungs. Each one that clears widens what a regulator has seen this class safely do.
• The last rung is still missing. Nobody — as of this writing — is running the large, long, expensive prevention trial that a “reduces sun damage for healthy fair-skinned people” claim would demand. That gap is institutional, not chemical, and it is the same gap it has always been.

So the honest reading is the optimistic-but-disciplined one this thread keeps returning to. The science is arriving through the front door. It is arriving as medicine — for pain, for pigment loss, for DNA damage — and not, so far, as the cosmetic the gray market has been counterfeiting for eighteen years. Anyone selling you that today, in a vial, from a website, is still the cautionary tale, not this page.

We’ll update this snapshot as the programs move. The next real marker is the dersimelagon decision in early 2027.